Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort Meeting Abstract
| Authors: | Segal, N. H.; Ou, S. H. I.; Balmanoukian, A. S.; Massarelli, E.; Brahmer, J. R.; Weiss, J.; Schoffski, P.; Antonia, S. J.; Massard, C.; Zandberg, D. P.; Maher, C.; Khleif, S.; Jin, X.; Rebelatto, M.; Steele, K.; Antal, J.; Gupta, A.; Spreafico, A. |
| Abstract Title: | Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort |
| Meeting Title: | 41st European Society for Medical Oncology Congress (ESMO) |
| Journal Title: | Annals of Oncology |
| Volume: | 27 |
| Issue: | Suppl. 6 |
| Meeting Dates: | 2016 Oct 7-11 |
| Meeting Location: | Copenhagen, Denmark |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2016-10-01 |
| Start Page: | vi328 |
| Language: | English |
| ACCESSION: | WOS:000393913000045 |
| DOI: | 10.1093/annonc/mdw376.01 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 949O -- Source: Wos |
